DOI QR코드

DOI QR Code

Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis

  • Zhao, Shuang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • He, Jin-Lan (Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • Qiu, Zhi-Xin (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • Chen, Nian-Yong (Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • Luo, Zhuang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • Chen, Bo-Jiang (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University) ;
  • Li, Wei-Min (Department of Respiratory Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University)
  • Published : 2014.08.30

Abstract

Background: CD44v6 (CD44 variant exon 6) is the chief CD44 variant isoform regulating tumor invasion, progression, and metastasis. The prognostic value of CD44v6 expression in non small cell lung cancer (NSCLC) has been evaluated in many studies, but the results have remained controversial. Thus, we performed a meta-analysis of currently available studies to investigate the prognostic value of CD44v6 expression in NSCLC patients and the relationship between the expression of CD44v6 and clinicopathological features. Materials and Methods: Two independent reviewers searched the relevant literature in Pubmed, Medline and Embase from 1946 to January 2014. Overall survival (OS) and various clinicopathological features were collected from included studies. This meta-analysis was accomplished using STATA 12.0 and Revman 5.2 software. Pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) were calculated to estimate the effects. Results: A total of 921 NSCLC patients from ten studies met the inclusion criteria. The results showed that CD44v6 high expression was a prognostic factor for poor survival (HR=1.91, 95%CI=1.12-3.26, p<0.05). With respect to clinicopathological features, CD44v6 high expression was related to histopathologic type (squamous cell carcinoma versus adenocarcinoma: OR=2.72, 95%CI=1.38-5.38, p=0.004), and lymph node metastasis (OR=3.02, 95%CI=1.93-4.72, p<0.00001). Conclusions: Our results suggested CD44v6 high expression as a poor prognostic factor for NSCLC, and CD44v6 expression is associated with lymph node metastasis and histopathologic type. Therefore, CD44v6 expression can be used as a novel prognostic marker in NSCLC cases.

Keywords

CD44 variant exon 6;non-small cell lung cancer;overall survival;meta-analysis

Acknowledgement

Supported by : Nature Science Foundation of China

References

  1. Afify AM, Tate S, Durbin-Johnson B, et al (2011). Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers, 26, 50-7. https://doi.org/10.5301/JBM.2011.6291
  2. Coradini D, Zorzet S, Rossin R, et al (2004). Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res, 10, 4822-30. https://doi.org/10.1158/1078-0432.CCR-04-0349
  3. Chen P, Huang HF, Lu R, et al (2012). Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia. Asian Pac J Cancer Prev, 13, 3791-4. https://doi.org/10.7314/APJCP.2012.13.8.3791
  4. Deng Z, Niu G, Cai L, et al (2013). The prognostic significance of CD44V6, CDH11, and $\beta$-Catenin expression in patients with osteosarcoma. Biomed Res Int, 2013, 496193.
  5. Fan CW, Wen L, Qiang ZD, et al (2012). Prognostic significance of relevant markers of cancer stem cells in colorectal cancer-a meta analysis. Hepatogastroenterology, 59, 1421-7.
  6. Fukuse T, Hirata T, Naiki H, et al (1999). Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer, 86, 1174-81. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1174::AID-CNCR11>3.0.CO;2-8
  7. Gunthert U, Hofmann M, Rudy W, et al (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24. https://doi.org/10.1016/0092-8674(91)90403-L
  8. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  9. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available:www.cochranehandbook. org. [updated March 2011]
  10. Hirata T, Fukuse T, Naiki H, et al (1998). Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic Factor. Cancer Res, 58, 1108-10.
  11. Jijiwa M, Demir H, Gupta S, et al (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKTmediated pathway. Plos One, 6, 24217. https://doi.org/10.1371/journal.pone.0024217
  12. Jung T, Gross W, Zoller M (2011). CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem, 286, 15862-74. https://doi.org/10.1074/jbc.M110.208421
  13. Kunlabut K, Vaeteewoottacharn K, Wongkham C, et al (2012). Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. Asian Pac J Cancer Prev, 13, 95-9.
  14. Kaufmann M, Heider KH, Sinn HP, et al (1995). CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345, 615-9. https://doi.org/10.1016/S0140-6736(95)90521-9
  15. Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
  16. Lee LN, Kuo SH, Lee YC, et al (2005). CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma. J Formos Med Assoc, 104, 541-8.
  17. Liu YJ, Yan PS, Li J, et al (2005). Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol, 11, 6601-6.
  18. Mayer B, Jauch KW, Gunthert U, et al (1993). De-novo expression of CD44 and survival in gastric cancer. Lancet, 342, 1019-22. https://doi.org/10.1016/0140-6736(93)92879-X
  19. Mackay CR, Terpe HJ, Stauder R, et al (1994). Expression and modulation of CD44 variant isoforms in humans. J Cell Biol, 124, 71-82. https://doi.org/10.1083/jcb.124.1.71
  20. Macaskill P, Walter SD, Irwig L (2001). A comparison of methods to detect publication bias in meta-analysis. Stat Med, 20, 641-54. https://doi.org/10.1002/sim.698
  21. Marhaba R, Bourouba M, Zoller M (2005). CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal, 17, 961-73. https://doi.org/10.1016/j.cellsig.2004.11.017
  22. Miyoshi T, Kondo K, Hino N, et al (1997). The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res, 3, 1289-97.
  23. Mei TH, Zhang GR, Ma Y (2004). The expression of vascular endothelial growth factor, CD44v6 in non-small cell lung carcinoma. Zhonghua Wai Ke Za Zhi, 42, 647-50.
  24. Naor D, Sionov RV, Ish-Shalom D (1997). CD44: structure, function, and association with the malignant process. Adv Cancer Res, 71, 241-319. https://doi.org/10.1016/S0065-230X(08)60101-3
  25. Nguyen VN, Mirejovsky T, Melinova L, et al (2000). CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma, 47, 400-8.
  26. Omran OM, Ata HS (2012). CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol, 36, 145-52. https://doi.org/10.3109/01913123.2011.651522
  27. Ramasami S, Kerr KM, Chapman AD, et al (2000). Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol, 192, 427-32. https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH741>3.0.CO;2-Z
  28. Sun BS, Li Y, Zhang ZF, et al (2013). Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg, 96, 1943-51. https://doi.org/10.1016/j.athoracsur.2013.07.089
  29. Su CY, Li YS, Han Y, et al (2014). Correlation between expression of cell adhesion molecules CD44v6 and E-cadherin and lymphatic metastasis in non- small cell lung cancer. Asian Pac J Cancer Prev, 15, 2221-4. https://doi.org/10.7314/APJCP.2014.15.5.2221
  30. Situ D, Long H, Lin P, et al (2010). Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res, 136, 1213-9.
  31. Shi J, Zhou Z, Di W, et al (2013). Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer, 13, 182. https://doi.org/10.1186/1471-2407-13-182
  32. Spaford MF, Koeppe J, Pan Z, et al (1996). Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 122, 627-32. https://doi.org/10.1001/archotol.1996.01890180035010
  33. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  34. Weng MX, Wu CH, Yang XP (2008). Expression and significance of E-cadherin, CD44v6, and proliferating cell nuclear antigen in non-small cell lung cancer. Ai Zheng, 27, 191-5.
  35. Wu Q, Jiang Y, Min J, et al (2005). Expression of CD44v6 and its prognostic significance in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 8, 215-8.
  36. Wielenga VJ, Heider KH, Offerhaus GJ, et al (1993). Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res, 53, 4754-6.
  37. Zhang L, Meng L, Wang L, et al (2004). The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 427-30.

Cited by

  1. Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis vol.10, pp.1, 2015, https://doi.org/10.1186/s13018-015-0328-z
  2. Expression and significance of CD44 and p-AKT in pancreatic head cancer vol.13, pp.1, 2015, https://doi.org/10.1186/s12957-015-0746-8
  3. Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts vol.32, pp.5, 2015, https://doi.org/10.1007/s12032-015-0593-z
  4. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component vol.23, pp.6, 2016, https://doi.org/10.1007/s12282-015-0653-4
  5. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy vol.36, pp.6, 2016, https://doi.org/10.3892/or.2016.5133
  6. Cancer stem cell molecular markers verified in vivo vol.11, pp.1, 2017, https://doi.org/10.1134/S1990750817010036
  7. Prognostic Evaluation of Vimentin Expression in Correlation with Ki67 and CD44 in Surgically Resected Pancreatic Ductal Adenocarcinoma vol.2017, pp.1687-630X, 2017, https://doi.org/10.1155/2017/9207616
  8. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer pp.1573-0646, 2017, https://doi.org/10.1007/s10637-017-0555-8
  9. Cell Membrane CD44v6 Levels in Squamous Cell Carcinoma of the Lung: Association with High Cellular Proliferation and High Concentrations of EGFR and CD44v5 vol.16, pp.3, 2015, https://doi.org/10.3390/ijms16034372
  10. Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors vol.11, pp.6, 2016, https://doi.org/10.3892/ol.2016.4493
  11. Prognostic value of cancer stem cell markers and E-cadherin expression in non-small-cell lung cancer vol.37, pp.2, 2017, https://doi.org/10.1097/01.XEJ.0000526548.59367
  12. Understanding the role of CD44V6 in ovarian cancer vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6377
  13. Lung cancer: active therapeutic targeting and inhalational nanoproduct design pp.1744-7593, 2018, https://doi.org/10.1080/17425247.2018.1547280
  14. Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells vol.8, pp.2, 2019, https://doi.org/10.3390/cells8020143